April 7, 2024
View Full PaperPlozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Key Points
Key points are not available for this paper at this time.
Abstract
Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic cardiovascular disease (ASCVD), nonalcoholic steatohepatitis, and acute pancreatitis. Despite available treatments, persistent ASCVD and acute pancreatitis-associated morbidity from sHTG remains.